Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT ID: NCT03248882

Last Updated: 2020-12-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

305 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-22

Study Completion Date

2019-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

PF-05221304 NAFLD NASH features of metabolic syndrome Dose-Ranging Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

C1171002 is a randomized, double blind, placebo controlled, 5 arm (placebo, plus 4 active doses of PF 05221304), parallel group study.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Double-Blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Double-Blind, PF-05221304-matching Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

PF-05221304 - 2 mg

PF-05221304 - 2 mg, once-daily

Group Type ACTIVE_COMPARATOR

PF-05221304

Intervention Type DRUG

PF-05221304, Experimental Drug

PF-05221304 - 10 mg

PF-05221304 - 10 mg, once-daily

Group Type ACTIVE_COMPARATOR

PF-05221304

Intervention Type DRUG

PF-05221304, Experimental Drug

PF-05221304 - 25 mg

PF-05221304 - 25 mg, once-daily

Group Type ACTIVE_COMPARATOR

PF-05221304

Intervention Type DRUG

PF-05221304, Experimental Drug

PF-05221304 - 50 mg

PF-05221304 - 50 mg, once-daily

Group Type ACTIVE_COMPARATOR

PF-05221304

Intervention Type DRUG

PF-05221304, Experimental Drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Placebo

Intervention Type DRUG

PF-05221304

PF-05221304, Experimental Drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index \>= 25 kg/m2
* Body Weight \> 50 kg
* Liver fat (assessed via MRI-PDFF) \>= 8%
* Biopsy-proven NASH - diagnosed in previous 24-months
* Presumed NASH - per Sponsor's definition
* NAFLD with minimal inflammation/fibrosis
* Features of Metabolic Syndrome

Exclusion Criteria

* Alcohol-induced steatohepatitis or other forms of chronic liver disease
* Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus
* Severe Renal Impairment
* Contraindications for MRI
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Franco Felizarta MD

Bakersfield, California, United States

Site Status

eStudySite

Chula Vista, California, United States

Site Status

San Diego Imaging Chula Vista

Chula Vista, California, United States

Site Status

University of California, San Diego (Altman Clinical and Translational Research Institute)

La Jolla, California, United States

Site Status

University of California, San Diego

La Jolla, California, United States

Site Status

eStudySite

La Mesa, California, United States

Site Status

Clinical Trials Research

Lincoln, California, United States

Site Status

National Research Institute

Los Angeles, California, United States

Site Status

Stanford University Medical Center, Blake wilbur Building

Palo Alto, California, United States

Site Status

Stanford University Medical Center

Palo Alto, California, United States

Site Status

Huntington Medical Research Institute

Pasadena, California, United States

Site Status

Inland Empire Liver Foundation

Rialto, California, United States

Site Status

Precision Research Institute

San Diego, California, United States

Site Status

Quest Clinical Research

San Francisco, California, United States

Site Status

South Denver Gastroenterology, P.C.

Englewood, Colorado, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Borland-Groover Clinic

Jacksonville, Florida, United States

Site Status

Schiff Center for Liver Diseases/University of Miami

Miami, Florida, United States

Site Status

Stand Up MRI of Miami

Miami, Florida, United States

Site Status

Ocean Blue Medical Research Center, Inc

Miami Springs, Florida, United States

Site Status

Avail Clinical Research, LLC

Orange City, Florida, United States

Site Status

Bioclinica Research

Orlando, Florida, United States

Site Status

Advanced Gastroenterology Associates, LLC

Palm Harbor, Florida, United States

Site Status

Qps-Mra, Llc

South Miami, Florida, United States

Site Status

Tampa General Medical Group

Tampa, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

South Florida Center Of Gastroenterology, PA

Wellington, Florida, United States

Site Status

Independent Imaging

Wellington, Florida, United States

Site Status

East-West Medical Research Institute

Honolulu, Hawaii, United States

Site Status

Invision Imaging

Honolulu, Hawaii, United States

Site Status

Midwest Institute for Clinical Research

Indianapolis, Indiana, United States

Site Status

Heartland Research Associates, LLC

Wichita, Kansas, United States

Site Status

Ascension Via Christi Imaging at St. Francis

Wichita, Kansas, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Digestive Disease Associates, PA

Catonsville, Maryland, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Mayo Clinic- Main Campus

Rochester, Minnesota, United States

Site Status

Gastrointestinal Associates, PA

Flowood, Mississippi, United States

Site Status

Colonnades at Baptist

Jackson, Mississippi, United States

Site Status

BioTelemetry Research

Rochester, New York, United States

Site Status

Investigational Drug Service, University of North Carolina Hospitals

Chapel Hill, North Carolina, United States

Site Status

The University of NC at Chapel Hill, Clinical and Translational Research Center (CTRC)

Chapel Hill, North Carolina, United States

Site Status

The University of North Carolina at Chapel Hill, Biomedical Research Imaging Center (MRI Facility)

Chapel Hill, North Carolina, United States

Site Status

Wake Research Associates, LLC

Raleigh, North Carolina, United States

Site Status

PMG Research of Wilmington, LLC

Wilmington, North Carolina, United States

Site Status

PMG Research, Inc.

Winston-Salem, North Carolina, United States

Site Status

Sterling Research Group, Ltd.

Cincinnati, Ohio, United States

Site Status

Prime Imaging (Chattanooga Outpatient Center)

Chattanooga, Tennessee, United States

Site Status

ClinSearch

Chattanooga, Tennessee, United States

Site Status

Touchstone

Austin, Texas, United States

Site Status

Baylor College of Medicine - Advanced Liver Therapies

Houston, Texas, United States

Site Status

Pinnacle Clinical Research

Rollingwood, Texas, United States

Site Status

Clinical Trials of Texas, Inc.

San Antonio, Texas, United States

Site Status

Pinnacle Clinical Research, PLLC

San Antonio, Texas, United States

Site Status

Clinical Research Advantage, Inc./Wasatch Peak Family Practice

Layton, Utah, United States

Site Status

National Clinical Research - Richmond, Inc.

Richmond, Virginia, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

Australian Clinical Research Network

Maroubra, New South Wales, Australia

Site Status

Spectrum Medical Imaging

Randwick, New South Wales, Australia

Site Status

Castlereagh Imaging

Westmead, New South Wales, Australia

Site Status

Storr Liver Centre, Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Dr. Jones & Partners Medical Imaging

Adelaide, South Australia, Australia

Site Status

Royal Adelaide Hospital, Department of Gastroenterology and Hepatology

Adelaide, South Australia, Australia

Site Status

Flinders Medical Centre/Department of Gastroenterology & Hepatology

Adelaide, South Australia, Australia

Site Status

Radiology SA

Adelaide, South Australia, Australia

Site Status

Royal Melbourne Hospital

Parkville, Victoria, Australia

Site Status

Dr TG Elliott Inc - BC Diabetes

Vancouver, British Columbia, Canada

Site Status

False Creek Healthcare Centre

Vancouver, British Columbia, Canada

Site Status

False Creek Healthcare

Vancouver, British Columbia, Canada

Site Status

LAIR Centre

Vancouver, British Columbia, Canada

Site Status

Discovery Clinical Services Ltd.

Victoria, British Columbia, Canada

Site Status

West Coast Medical Imaging

Victoria, British Columbia, Canada

Site Status

Nova Scotia Health Authority, QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Nova Scotia Health Authority, QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Nova Scotia Health Authority - QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Aggarwal and Associates Limited

Brampton, Ontario, Canada

Site Status

St. Joseph's Health Care London

London, Ontario, Canada

Site Status

London Health Sciences Centre - University Hospital

London, Ontario, Canada

Site Status

Oxford Medical Imaging

Mississauga, Ontario, Canada

Site Status

LMC Clinical Research Inc. (Bayview)

Toronto, Ontario, Canada

Site Status

St. Michael's Hospital - MRI Research Centre

Toronto, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

University Health Network (UHN) - Toronto General Hospital - Toronto Centre for Liver Disease (TCLD)

Toronto, Ontario, Canada

Site Status

University of Toronto - Toronto General Hospital

Toronto, Ontario, Canada

Site Status

University Health Network (UHN)

Toronto, Ontario, Canada

Site Status

Toronto Liver Centre - Liver Care Centre Corporation

Toronto, Ontario, Canada

Site Status

Resonance Magnetique du Saguenay-Lac-Saint-Jean

Chicoutimi, Quebec, Canada

Site Status

Ecogene-21

Chicoutimi, Quebec, Canada

Site Status

Medpharmgene Inc

Montreal, Quebec, Canada

Site Status

Clinique de Medecine Urbaine du Quartier Latin

Montreal, Quebec, Canada

Site Status

Centre de recherche du CHUM

Montreal, Quebec, Canada

Site Status

Cedar Cancer Center - McGill University Health Centre

Montreal, Quebec, Canada

Site Status

Chronic Viral Illness Service - Royal Victoria Hospital - McGill University Health Centre (MUHC)

Montreal, Quebec, Canada

Site Status

McGill University Health Centre

Montreal, Quebec, Canada

Site Status

Research Institute of the MUHC

Montreal, Quebec, Canada

Site Status

Radiologie Varad

Montreal, Quebec, Canada

Site Status

IRM Quebec

Québec, Quebec, Canada

Site Status

IRM Quebec

Québec, Quebec, Canada

Site Status

CHU de Quebec - Universite Laval - site Centre Hospitalier de l'Universite Laval (CHUL)

Québec, Quebec, Canada

Site Status

Centre de recherche de l'Institut Universitaire de Cardiologie et de pneumologie de Quebec

Québec, Quebec, Canada

Site Status

Centre de recherche Saint-Louis

Québec, Quebec, Canada

Site Status

IRM Québec - Clinique St-Louis

Québec, Quebec, Canada

Site Status

Alpha Recherche Clinique

Québec, Quebec, Canada

Site Status

Clinix

Québec, Quebec, Canada

Site Status

Recherche Medicale St-Jerome Inc

Saint-Jérôme, Quebec, Canada

Site Status

Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Estrie

Sherbrooke, Quebec, Canada

Site Status

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Hadassah Hebrew University Medical Center - Ein Kerem

Jerusalem, , Israel

Site Status

Galilee Medical Center

Nahariya, , Israel

Site Status

Holy Family Hospital

Nazareth, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

The Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Tel-Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

ClinicMed Badurski i wspolnicy Spolka Jawna

Bialystok, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Gdansku

Gdansk, , Poland

Site Status

Centrum Badan Klinicznych PI-House Sp. z o.o.

Gdansk, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Gdyni

Gdynia, , Poland

Site Status

Osrodek Badan Klinicznych

Jaworze, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Katowicach

Katowice, , Poland

Site Status

Silmedic Sp. z o.o. Oddzial w Katowicach

Katowice, , Poland

Site Status

Centrum Medyczne A-Z Clinic

Krakow, , Poland

Site Status

Krakowskie Centrum Medyczne sp. z o.o.

Krakow, , Poland

Site Status

Gabinet Lekarski Malgorzata Saryusz-Wolska

Lodz, , Poland

Site Status

Synexus Polska Sp. z o.o Oddzial w Poznaniu

Poznan, , Poland

Site Status

Centrum Medyczne Medyk

Rzeszów, , Poland

Site Status

Synexus Polska Sp. z o. o. Oddzial w Warszawie

Warsaw, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej Centrum Badan Klinicznych

Wroclaw, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial we Wroclawiu

Wroclaw, , Poland

Site Status

DOBROSTAN - Gabinety Lekarskie

Wroclaw, , Poland

Site Status

Changhua Christian Hospital

Changhua, Changhua County, Taiwan

Site Status

Chung-Ho Memorial Hospital, Kaohsiung Medical University

Kaohsiung City, , Taiwan

Site Status

National Cheng-Kung University Hospital

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Israel Poland Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Sivakumar P, Saul M, Robinson D, King LE, Amin NB. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH). Sci Rep. 2024 Jul 24;14(1):17072. doi: 10.1038/s41598-024-67843-8.

Reference Type DERIVED
PMID: 39048608 (View on PubMed)

Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, Tuthill TA, Kou K, Boucher M, Tesz G, Dullea R, Bence KK, Kim AM, Pfefferkorn JA, Esler WP. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021 Oct;27(10):1836-1848. doi: 10.1038/s41591-021-01489-1. Epub 2021 Oct 11.

Reference Type DERIVED
PMID: 34635855 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=C1171002

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-001156-55

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

C1171002

Identifier Type: -

Identifier Source: org_study_id